Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient

International Journal of Molecular Sciences

Serge Mordon¹  Nadira Delhem¹  Clara Milhem¹  Olivier Moralès¹  Céline Ingelaere²  Laurent Mortier³  David Pasquier⁴  Xavier Mirabel⁴ 

[1] INSERM, CHU-Lille, U1189—ONCO-THAI—Assisted Laser Therapy and Immunotherapy for Oncology, University of Lille, F-59000 Lille, France;Immune Insight, Institut de Biologie de Lille, 59021 Lille, France;Service de Dermatologie, Hôpital Huriez, 59000 Lille, France;Service de Radiothérapie, Centre Oscar Lambret, 59000 Lille, France;

关键词: stereotaxic radiotherapy;    immunotherapy;    anti-PD1;    melanoma;    immune response;   

DOI  :  10.3390/ijms21186772

来源: DOAJ

【 摘 要 】

The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now to select good responder patients by identifying early biomarkers to propose therapeutic combinations that potentiate the efficacy of the therapy. Here we report the case of a 60-year-old man with superficial melanoma treated with high-dose hypo fractionated radiotherapy (H-SRT) combined with a single dose of anti-PD1 immunotherapy (Nivolumab) for a metastatic lymph node recurrence due to cancer progression. In this study, we present the results obtained regarding the activation of the Th1 immune response after H-SRT treatment followed by anti PD-1 therapeutic protocol. These results were correlated with clinical data to identify potential immunological biomarkers of treatment efficacy. This exceptional case report shows that a combination of H-SRT with a single dose of anti-PD1 immunotherapy may allow a better activation of the immune response in favor of a complete clinical response.

【 授权许可】

Unknown